399 related articles for article (PubMed ID: 22005599)
1. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
[TBL] [Abstract][Full Text] [Related]
2. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
3. Involvement of norepinephrine and serotonin system in antidepressant-like effects of hederagenin in the rat model of unpredictable chronic mild stress-induced depression.
Liang BF; Huang F; Wang HT; Wang GH; Yuan X; Zhang MZ; Guo HB; Cheng YF; Xu JP
Pharm Biol; 2015 Mar; 53(3):368-77. PubMed ID: 25471378
[TBL] [Abstract][Full Text] [Related]
4. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
5. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes.
Xie Z; Westmoreland SV; Miller GM
J Pharmacol Exp Ther; 2008 May; 325(2):629-40. PubMed ID: 18310473
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
7. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
8. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vesicular uptake of monoamines by hyperforin.
Roz N; Mazur Y; Hirshfeld A; Rehavi M
Life Sci; 2002 Sep; 71(19):2227-37. PubMed ID: 12215370
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
11. Caulis Sinomenii extracts activate DA/NE transporter and inhibit 5HT transporter.
Zhao G; Bi C; Qin GW; Guo LH
Exp Biol Med (Maywood); 2009 Aug; 234(8):976-85. PubMed ID: 19491370
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract.
Zhao G; Jiang ZH; Zheng XW; Zang SY; Guo LH
Pharmacol Biochem Behav; 2008 Sep; 90(3):363-71. PubMed ID: 18485464
[TBL] [Abstract][Full Text] [Related]
13. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
Han DD; Gu HH
BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain.
Rothman RB; Katsnelson M; Vu N; Partilla JS; Dersch CM; Blough BE; Baumann MH
Eur J Pharmacol; 2002 Jun; 447(1):51-7. PubMed ID: 12106802
[TBL] [Abstract][Full Text] [Related]
17. Cynomorium songaricum extracts functionally modulate transporters of gamma-aminobutyric acid and monoamine.
Zhao G; Wang J; Qin GW; Guo LH
Neurochem Res; 2010 Apr; 35(4):666-76. PubMed ID: 20084455
[TBL] [Abstract][Full Text] [Related]
18. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
[TBL] [Abstract][Full Text] [Related]
19. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.
Miller DK; Wong EH; Chesnut MD; Dwoskin LP
J Pharmacol Exp Ther; 2002 Aug; 302(2):687-95. PubMed ID: 12130733
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR.
Rickli A; Kolaczynska K; Hoener MC; Liechti ME
Neurotoxicology; 2019 May; 72():95-100. PubMed ID: 30776375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
